Cargando…

MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary

BACKGROUND: MicroRNAs (miRNA) are 20∼25 nucleotide non-coding RNAs that inhibit the translation of targeted mRNA, and they have been implicated in the development of human malignancies. High grade serous ovarian carcinomas, the most common and lethal subtype of ovarian cancer, can occur sporadically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Cheng-Han, Subramanian, Subbaya, Beck, Andrew H., Espinosa, Inigo, Senz, Janine, Zhu, Shirley X., Huntsman, David, van de Rijn, Matt, Gilks, C. Blake
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749450/ https://www.ncbi.nlm.nih.gov/pubmed/19798417 http://dx.doi.org/10.1371/journal.pone.0007314

Ejemplares similares

Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
por: Pradhan, Manohar, et al.
Publicado: (2010)

Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden
por: Anglesio, Michael S, et al.
Publicado: (2015)

Prediction of carrying a BRCA1 or BRCA2 mutation
por: Lee, Kyung-Hun
Publicado: (2023)

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
por: Bashashati, Ali, et al.
Publicado: (2013)

A Patient Affected with Serous Ovarian/Peritoneal Carcinoma Carrying the FANCM Mutation
por: Nikolaidi, Adamantia, et al.
Publicado: (2019)

Is there a difference in testosterone levels and its regulators in men carrying BRCA mutations?
por: Goldberg, Hanan, et al.
Publicado: (2017)

Physical activity and sleep behaviour in women carrying BRCA1/2 mutations
por: Galasso, Letizia, et al.
Publicado: (2022)

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation in Asian breast cancer patients
por: Ang, Boon Hong, et al.
Publicado: (2022)

Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations
por: Shalabi, Sundus F., et al.
Publicado: (2021)

Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets
por: De, Alok, et al.
Publicado: (2020)

Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view
por: De Felice, Francesca, et al.
Publicado: (2015)

Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation
por: Metcalfe, Kelly A, et al.
Publicado: (2007)

The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors()()
por: Wang, Yemin, et al.
Publicado: (2015)

Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA)
por: Apicella, Carmel, et al.
Publicado: (2003)

Author Correction: Physical activity and sleep behaviour in women carrying BRCA1/2 mutations
por: Galasso, Letizia, et al.
Publicado: (2022)

Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a “low-grade serous tubal intra-epithelial carcinoma” (STIC) on risk reducing surgery
por: Chay, Wen Yee, et al.
Publicado: (2015)

High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary
por: Matulonis, Ursula A., et al.
Publicado: (2011)

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2010)

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum
por: Gershenson, David M, et al.
Publicado: (2015)

Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma
por: Dai, Ying, et al.
Publicado: (2018)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery
por: Salhab, Mohamed, et al.
Publicado: (2010)

Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements
por: Turashvili, Gulisa, et al.
Publicado: (2020)

Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
por: Gilks, C. Blake
Publicado: (2010)

Non-neoplastic Fallopian Tube Epithelium Carrying Gene Mutations of a Novel SOX2 Repressor Region is Soil of High-grade Serous Ovarian Cancer
por: Hirohashi, Yoshihiko, et al.
Publicado: (2016)

Pollitt syndrome patients carry mutation in TTDN1
por: Swagemakers, Sigrid M.A., et al.
Publicado: (2014)

Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary
por: Xu, Yan, et al.
Publicado: (2017)

Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes
por: Budryk, M, et al.
Publicado: (2012)

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer
por: Kim, Se Ik, et al.
Publicado: (2019)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients
por: Ji, Gang, et al.
Publicado: (2021)

Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report
por: Zhao, Fengjiao, et al.
Publicado: (2020)

Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience
por: Hur, Joon Young, et al.
Publicado: (2020)

STING pathway expression in low‐grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
por: Huvila, Jutta, et al.
Publicado: (2021)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019)

Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer
por: Cardenas, Horacio, et al.
Publicado: (2019)

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
por: Launonen, I.-M., et al.
Publicado: (2022)

The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors
por: Schrader, Kasmintan A., et al.
Publicado: (2009)

An Estimate of the Average Number of Recessive Lethal Mutations Carried by Humans
por: Gao, Ziyue, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_060d0hp356k3b1e5r2q4dbh6pp